A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5437-5447

  Nikolic, Dragana ^a   Banach, Maciej ^b   Nikfar, Shekoufeh ^c,d   Salari, Pooneh ^e   Mikhailidis, Dimitri P ^f   Toth, Peter P ^g   Abdollahi, Mohammad ^h   Ray, Kausik K ⁱ   Pencina, Michael J ^j   Malyszko, Jolanta ^k   Rysz, Jacek ^b   Rizzo, Manfredi ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

more..

Author keywords

Chronic kidney disease; Creatinine; Dialysis; Meta analysis; Renal outcomes; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROID;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; META ANALYSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

CHRONIC KIDNEY DISEASE; CREATININE; DIALYSIS; META-ANALYSIS; RENAL OUTCOMES; STATIN;

BLOOD UREA NITROGEN; CARDIOVASCULAR DISEASES; CREATININE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84887210473     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.060     Document Type: Article

References (76)

1. K. Uhlig, A.S. Levey, and M.J. Sarnak Traditional cardiac risk factors in individuals with chronic kidney disease Semin Dial 16 2003 118 127
2. A. Gluba, D.P. Mikhailidis, G.Y. Lip, S. Hannam, J. Rysz, and M. Banach Metabolic syndrome and renal disease Int J Cardiol 164 2 2013 141 150
3. D. Nikolic, S. Nikfar, P. Salari Lipid and Blood Pressure Meta-Analysis Collaboration Group Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials Curr Med Res Opin 29 5 2013 435 451
4. A. Gluba, J. Rysz, and M. Banach Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 11 16 2010 2665 2674
5. M. Banach, and J. Rysz Current problems in hypertension and nephrology Expert Opin Pharmacother 11 16 2010 2575 2578
6. C.J. Lintott, R.S. Scott, J.M. Bremer, and B.I. Shand Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency Am J Cardiol 76 2 1995 97A 101A
7. M. Barylski, S. Nikfar, and D.P. Mikhailidis Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants Pharmacol Res 72C 2013 35 44
8. J. Rysz, W.S. Aronow, R.S. Stolarek, S. Hannam, D.P. Mikhailidis, and M. Banach Nephroprotective and clinical potential of statins in dialyzed patients Expert Opin Ther Targets 13 5 2009 541 550
9. P.M. Ridker, C.P. Cannon, D. Morrow, and E. Braunwald Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) investigators: C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
10. M. Tonelli, C. Isles, and G.C. Curhan Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563
11. R. Fathi, N. Isbel, L. Short, B. Haluska, S. Johnson, and T.H. Marwick The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease Am J Kidney Dis 43 2004 45 52
12. V. Panichi, S. Paoletti, and E. Mantuano In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients Nephrol Dial Transplant 21 2006 337 344
13. M. Epstein, and V.M. Campese Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors on renal function Am J Kidney Dis 45 2005 2 14
14. M. Tonelli, L. Moye, F.M. Sacks, T. Cole, G.C. Curhan for the Cholesterol and Recurrent Events (CARE) Trial Investigators Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 2003 1605 1613
15. M.J. Koren, M.H. Davidson, and D.J. Wilson Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD Am J Kidney Dis 53 2009 741 750
16. H. Nakamura, K. Mizuno, and Y. Ohashi Pravastatin. and cardiovascular risk in moderate chronic kidney disease Atherosclerosis 206 2 2009 512 517
17. M. Tonelli, C. Isles, and T. Craven Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171 178
18. S. Bianchi, R. Bigazzi, A. Caiazza, and V.M. Campese A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 3 2003 565 570
19. V.G. Athyros, D.P. Mikhailidis, and A.A. Papageorgiou The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study J Clin Pathol 57 2004 728 734
20. J. Shepherd, J.J.P. Kastelein, V. Bittner for the TNT (Treating to New Targets) Investigators Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study Clin J Am Soc Nephrol 2 2007 1131 1139
21. J. Atthobari, A.H. Brantsma, and R.T. Gansevoort The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol Dial Transplant 21 2006 3106 3114
22. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 7 2006 2006 2016
23. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
24. Y. Sawara, T. Takei, and K. Uchida Effects of lipid-lowering therapy with rosuvastatin on atherosclerosis burden in patients with chronic kidney disease Int Med 47 2008 1505 1510
25. J.E. Burmeister, D.R. Miltersteiner, and B.M. Campos Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein J Nephrol 22 2009 83 89
26. M. Arabul, M. Gullulu, and Y. Yilmaz Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease Clin Biochem 41 2008 1055 1058
27. A. Ichihara, M. Hayashi, M. Ryuzaki, M. Handa, T. Furukawa, and T. Saruta Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus Nephrol Dial Transplant 17 2002 1513 1517
28. M.S. Joy, K.A. Dornbrook-Lavender, H. Chin, S.L. Hogan, and C. Denu-Ciocca Effects of atorvastatin on LP(a) and lipoprotein profiles in hemodialysis patients Ann Pharmacother 42 2008 9 15
29. T. Nakamura, T. Sugaya, Y. Kawagoe, T. Suzuki, T. Inoue, and K. Node Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease Am J Nephrol 26 2006 82 86
30. R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghty, and J.S. Coombes Effect of atorvastatin on kidney function in chronic kidney disease: a randomized double-blind placebo-controlled trial Atherosclerosis 213 2010 218 224
31. T. Nakamura, C. Ushiyama, and K. Hirokawa Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis Nephrol Dial Transplant 17 2002 798 802
32. Y. Imai, H. Suzuki, T. Saito, I. Tsugi, K. Abe, and T. Saruta The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia Clin Exp Hypertens 21 8 1999 1345 1355
33. V.G. Athyros, D.P. Mikhailidis, and E.N. Liberopoulos Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome. A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol Dial Transplant 22 2007 118 127
34. A. Verma, K.M. Ranganna, R.S. Reddy, M. Verma, and N.F. Gordon Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease Am J Cardiol 96 2005 1290 1292
35. R.G. Fassett, J.S. Coombes, D. Packham, K.F. Fairley, and P. Kincaid-Smith Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease Scand J Urol Nephrol 44 2010 56 61
36. O.A. Geith, M.A.K. Sobh, and K.E.S. Mohamed Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephritic syndrome Nephron 91 2002 612 619
37. M. Goicoechea, S. García de Vinuesa, and V. Lahera Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease J Am Soc Nephrol 17 2006 S231 S235
38. R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghy, J.E. Sharman, and J.S. Coombes Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomized controlled trial J Atheroscler Thromb 17 3 2010 235 241
39. R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghty, J.W. Cardinal, and J.S. Coombes Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial Nephrol Dial Transplant 27 2012 182 189
40. J.E. Sidaway, R.G. Davidson, and F. McTaggart Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor mediated endocytosis in opossum kidney cells J Am Soc Nephrol 15 2004 2258 2265
41. A. Verhulst, P.C. D'Haese, and M.E. De Broe Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells J Am Soc Nephrol 15 2004 2249 2257
42. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 2001 260 269
43. Heart Protection Study Collaborative Group MRC/BHF Heeeart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial Lancet 360 2002 7 22
44. M. Banach, S. Nikfar, R. Rahimi Lipid and Blood Pressure Meta-Analysis Collaboration Group The effects of statins on blood pressure in normotensive or hypertensive subjects - A meta-analysis of randomized controlled trials Int J Cardiol Apr 18 2013 10.1016/j.ijcard.2013.03.068
45. V.G. Athyros, A.I. Hatzitolios, A. Karagiannis IMPERATIVE Collaborative Group IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis Arch Med Sci 7 6 2011 984 992
46. M.P. O'Donnell, B.L. Kasiske, and Y. Kim Lovastatin retards the progression of established glomerular disease in obese Zucker rats Am J Kidney Dis 22 1993 83 89
47. V.M. Campese, M.K. Nadim, and M. Epstein Are 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors renoprotective? J Am Soc Nephrol 16 2005 S11 S17
48. M. Joyce, C. Kelly, and D. Winter Pravastatin, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion J Surg Res 101 2001 79 84
49. E.G. Lowrie, and N. Lew Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 1990 458
50. M. Avram, P. Fein, and L. Bonomini Predictors of survival in continuous ambulatory peritoneal dialysis patients: a five-year prospective study Perit Dial Int 16 1996 S190
51. J.W. Chang, W.S. Yang, and W.K. Min Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients Am J Kidney Dis 39 2002 1213 1217
52. M. Barylski, J. Małyszko, J. Rysz, M. Myśliwiec, and M. Banach Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 7 6 2011 1055 1066
53. L. Vernaglione, C. Cristofano, and P. Muscogiuri Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 43 2004 471 478
54. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann Intern Med 145 2 2006 117 124
55. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, N. Shimada, and H. Koide Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia Am J Nephrol 21 2001 449 454
56. G. Tonolo, M. Ciccarese, and P. Brizzi Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment Diabetes Care 20 1997 1891 1895
57. H.M. Lai, W.S. Aronow, and A.D. Mercando The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice Arch Med Sci 8 1 2012 53 56
58. J. Joven, C. Villabona, E. Vitella, L. Masana, R. Alberti, and M. Valles Abnormalities of lipoprotein metabolism in patients with nephrotic syndrome N Engl J Med 323 1990 579 584
59. W.Q. Yang, N.G. Song, and S.S. Ying Serum lipid concentrations correlate with the progression of chronic renal failure Clin Lab Sci 12 1999 104 108
60. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 7645 2008 645 651
61. M. Banach, D.P. Mikhailidis, S.E. Kjeldsen, and J. Rysz Time for new indications for statins? Med Sci Monit 15 12 2009 MS1 MS5
62. T.M. Lee, S.F. Su, and C.H. Tsai Effect of pravastatin on proteinuria in patients with well-controlled hypertension Hypertension 40 2002 67 73
63. A. Shekhar Pandey, S. Bissonnette, S. Boukas, E. Rampakakis, and J.S. Sampalis Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial Arch Med Sci 7 5 2011 767 775
64. A. Gluba, M. Banach, S. Hannam, D.P. Mikhailidis, A. Sakowicz, and J. Rysz The role of Toll-like receptors in renal diseases Nat Rev Nephrol 6 4 2010 224 235
65. J. Rysz, E. Majewska, R.A. Stolarek, M. Banach, A. Ciałkowska- Rysz, and Z. Baj Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis Am J Nephrol 26 5 2006 437 444
66. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 1 2001 64 70
67. J.F. Navarro, C. Mora, M. Muros, and G. Garcia-Idoate Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis Nephron Clin Pract 95 2003 c128 c135
68. G.A.A. Ferns Differential effects of statins on serum CRP levels: implications of recent clinical trials Atherosclerosis 169 2003 349 351
69. B. Genser, T. Grammer, and T. Stojakovic Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis Int J Clin Pharmacol Ther 46 2008 497 510
70. V.G. Athyros, A. Karagiannis, E.S. Ganotakis Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin 27 8 2011 1659 1668
71. W. Hou, J. Lv, and V. Perkovic Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 24 2013 1807 1817
72. D.G. Vidt, S. Harris, and F. McTaggart Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate Am J Cardiol 97 2006 1602 1606
73. J. Sorof, C. Berne, A. Siewert-Delle, L. Jorgensen, P. Sager URANUS Study Investigators Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients Diabetes Res Clin Pract 72 1 2006 81 87
74. S.C. Palmer, J.C. Craig, S.D. Navaneethan, M. Tonelli, F. Pellegrini, and G.F. Strippoli Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 4 2012 263 275
75. A. Upadhyay, A. Earley, J.L. Lamont, S. Haynes, C. Wanner, and E.M. Balk Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 4 2012 251 262
76. C. Baigent, M.J. Landray, C. Reith SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 2011 2181 2192